Skip to main content
. Author manuscript; available in PMC: 2017 Jan 3.
Published in final edited form as: Nat Rev Clin Oncol. 2012 Sep 11;9(11):643–653. doi: 10.1038/nrclinonc.2012.156

Table 2.

Diagnostic platforms used to guide treatment decisions

Drug Cancer Target/biomarker Diagnostic method
Rituximab B-cell NHL CD20 IHC, flow cytometry
Brentuximab
vedotin		 Hodgkin lymphoma
and ALCL		 CD30 IHC, flow cytometry
Tamoxifen Breast Oestrogen receptor IHC
Imatinib CML ABL PCR
Trastuzumab Breast HER2
HER2 		IHC
FISH
Crizotinib NSCLC EML4/ALK FISH
Vemurafinib Melanoma BRAF V600 RT-PCR
Adjuvant therapy for
breast carcinoma		 Breast Oestrogen receptor,
progesterone
receptor, HER2		 RT-PCR
Adjuvant therapy for
breast carcinoma		 Breast 70 genes
(MammaPrint)		 GEP
Adjuvant therapy for
colon carcinoma		 Colon 12 genes RT-PCR
Gefitinib or erlotinib Lung EGFR mutation PCR
Gefitinib or erlotinib Colon, lung KRAS mutation PCR

Abbreviations: ALCL, anaplastic large-cell lymphoma; CML, chronic myeloid leukaemia; FISH, fluorescence in situ hybridization; GEP, gene-expression profiling; IHC, immunohistochemistry; NHL, non-Hodgkin lymphoma; NSCLC, non-small-cell lung cancer; RT-PCR, reverse transcription-PCR.